Clinical trials: Gram-positive Bacterial Infections
Streptococcal Pharyngitis, Group A Streptococcal Infection
A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis
The goal of this observational study is to learn how well the SalivIQ™ Strep A test detects Group A Streptococcus, the bacteria that cause strep throat.
- Trial name
- NCT07891728
- Testing
- qPCR
- Where
- 3 sites in United States
- Volunteers
- 668 people
- Sponsor
- SalivIQ Diagnostics, Inc.
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 administered subcutaneously or intramuscularly in healthy Japanese infants (3 months of age).
- Trial name
- NCT03848065
- Testing
- V114, Pneumococcal 13-valent Conjugate Vaccine (PCV13), Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
- Where
- 14 sites in Japan
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcal Infections
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant.
- Trial name
- NCT07085702
- Testing
- Low dose Strep A Alum, Medium dose Strep A Alum, High dose Strep A Alum
- Where
- 2 sites in Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722). The objectives are: To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01444781
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Staphylococcal Skin Infections
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults
- Trial name
- NCT00463801
- Testing
- Daptomycin
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Novartis
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Adults
A Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in adults aged 18 years and older.
- Trial name
- NCT06474377
- Testing
- Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Pneumovax®
- Where
- China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Diphtheria, Tetanus
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children
This study will evaluate the safety and reactogenicity of GSK Biologicals' combined reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™ when given as a single injection to 6-10 year old…
- Conditions
- Diphtheria, Tetanus, Acellular Pertussis
- Trial name
- NCT01988857
- Testing
- Boostrix™
- Where
- Vietnam
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gram Positive Bacterial Infection
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected…
- Trial name
- NCT01019395
- Testing
- Daptomycin
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine
This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.
- Trial name
- NCT02079207
- Testing
- NBP606, Prodiax-23
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Diphtheria, Tetanus
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Objectives: To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00802867
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- Where
- 19 sites in United States
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
This study is designed to assess the safety, tolerability, and immunogenicity of V114 compared with Prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
- Trial name
- NCT02573181
- Testing
- V114, Prevnar 13™
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of…
- Trial name
- NCT03565900
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Anthrax
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent…
- Trial name
- NCT07268612
- Testing
- CYFENDUS
- Volunteers
- 250 people
- Sponsor
- Emergent BioSolutions
Clostridium Infections, Diarrhea
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT00468728
- Testing
- PAR-101/OPT-80, Vancomycin
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 535 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diphtheria, Acellular Pertussis
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00263692
- Testing
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Where
- 15 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis, Pulmonary
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
To determine the pharmacokinetics of ethionamide (Eto) and ethionamide-sulfoxide (Eto-SO) in participants with tuberculosis (TB) when Eto is dosed under programmatic conditions.
- Trial name
- NCT05258877
- Testing
- Plasma samples
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- BioVersys AG
Gram-Positive Bacterial Infections
Post Marketing Surveillance Study on Linezolid
The purpose of this study is to determine if Linezolid is safe for adult Filipino patients diagnosed with gram positive infections.
- Trial name
- A5951090 (NCT01564758)
- Testing
- Linezolid
- Volunteers
- 99 people
- Sponsor
- Pfizer
Gram-Positive Bacterial Infections, Staphylococcus Infections
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
- Conditions
- Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
- Trial name
- NCT00079976
- Testing
- Tigecycline
- Volunteers
- 174 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Streptococcal
Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals' pneumococcal vaccine (2830929A and 2830930A) administered as 3-dose primary vaccination during the first…
- Trial name
- NCT01616459
- Testing
- Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™
- Where
- 42 sites in Czechia, Germany and 2 more
- Volunteers
- 953 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline